Gaia Griguolo· @GaiaGriguolo · X·· 2 天前评分90
正文 · 原文
TALENT trial at #ESMO26
Neoadjuvant T-DXd +/- anastrozole or sequentially with TCx4 shows modest activity in HER2-low Hr+ early BC
pCR TDXd 7%, TDXd +anastroxole 3%, TDXd x 4 -> TC×4 9%
High baseline levels of HER2 prot potentially associated with higher pCR rates
@OncoAlert
270 浏览 · 7 赞 · 7 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Gaia Griguolo · x.com